If I recall correctly, the IP associated with therapeutic use of Apo A1 Milano still resides in the sub-basement of Pfizer as a result of the Esperion purchase?
It was licensed by MDCO in late 2009 (#msg-44863685).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”